RAPT

RAPT Therapeutics Inc

RAPT, USA

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

https://www.rapt.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RAPT
stock
RAPT

(RAPT) Risk Channels and Responsive Allocation news.stocktradersdaily.com

Read more →
RAPT
stock
RAPT

H.C. Wainwright Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $72 富途牛牛

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$65

Analyst Picks

Strong Buy

1

Buy

1

Hold

4

Sell

1

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

6.53

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-11.57 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.61 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 99.81% of the total shares of RAPT Therapeutics Inc

1.

Medicxi Ventures Management (Jersey) Ltd

(16.8946%)

since

2025/06/30

2.

Orbimed Advisors, LLC

(9.9282%)

since

2025/06/30

3.

TCG Crossover Management, LLC

(9.8942%)

since

2025/06/30

4.

Foresite Capital Management VI LLC

(9.4481%)

since

2025/06/30

5.

RTW INVESTMENTS, LLC

(8.8917%)

since

2025/06/30

6.

Bvf Inc

(6.9821%)

since

2025/06/30

7.

Nantahala Capital Management, LLC

(5.7542%)

since

2025/06/30

8.

Vanguard Group Inc

(5.3214%)

since

2025/06/30

9.

ADAR1 Capital Management LLC

(4.7359%)

since

2025/06/30

10.

Deep Track Capital, LP

(4.5437%)

since

2025/06/30

11.

Vanguard Total Stock Mkt Idx Inv

(4.0551%)

since

2025/07/31

12.

Redmile Group, LLC

(3.8136%)

since

2025/06/30

13.

FCPM III SERVICES BV

(2.6616%)

since

2025/06/30

14.

Perceptive Advisors LLC

(1.1119%)

since

2025/06/30

15.

Column Group LLC

(1.0042%)

since

2025/03/31

16.

Geode Capital Management, LLC

(0.8469%)

since

2025/06/30

17.

Vanguard Institutional Extnd Mkt Idx Tr

(0.723%)

since

2025/07/31

18.

BlackRock Inc

(0.5433%)

since

2025/06/30

19.

Euclidean Capital LLC

(0.4972%)

since

2025/06/30

20.

Renaissance Technologies Corp

(0.3778%)

since

2025/06/30

21.

Fidelity Extended Market Index

(0.3405%)

since

2025/07/31

22.

Two Sigma Investments LLC

(0.2638%)

since

2025/06/30

23.

Extended Equity Market Fund K

(0.1328%)

since

2025/06/30

24.

Fidelity Total Market Index

(0.1223%)

since

2025/07/31

25.

Fidelity Series Total Market Index

(0.0898%)

since

2025/07/31

26.

Fidelity Nasdaq Composite Index

(0.0858%)

since

2025/07/31

27.

Spartan Extended Market Index Pool F

(0.0805%)

since

2025/07/31

28.

AJU IB Investment Co Ltd

(0.0752%)

since

2025/03/31

29.

NT Ext Equity Mkt Idx Fd - NL

(0.0738%)

since

2025/06/30

30.

Northern Trust Extended Eq Market Idx

(0.0735%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - L

(0.0735%)

since

2025/06/30

32.

Schwab Total Stock Market Index

(0.0605%)

since

2025/07/31

33.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0573%)

since

2025/06/30

34.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.054%)

since

2025/07/31

35.

Invesco RAFI US 1500 Small-Mid ETF

(0.0516%)

since

2025/08/29

36.

Goldman Sachs Small Cap Eq Insghts Instl

(0.0473%)

since

2025/04/30

37.

Goldman Sachs Small Cp Val Insghts Instl

(0.0468%)

since

2025/04/30

38.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0255%)

since

2025/03/31

39.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0179%)

since

2024/12/31

40.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0059%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.65

EPS Estimate

-0.1085

EPS Difference

-0.5415

Surprise Percent

-499.0783%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.